Cite
Rationale and design of the PREVENT-HIT study: A randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis
MLA
Frame, James N., et al. “Rationale and Design of the PREVENT-HIT Study: A Randomized, Open-Label Pilot Study to Compare Desirudin and Argatroban in Patients with Suspected Heparin-Induced Thrombocytopenia with or without Thrombosis.” Clinical Therapeutics, vol. 32, no. 4, Apr. 2010, pp. 626–36. EBSCOhost, https://doi.org/10.1016/j.clinthera.2010.04.012.
APA
Frame, J. N., Rice, L., Bartholomew, J. R., & Whelton, A. (2010). Rationale and design of the PREVENT-HIT study: A randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clinical Therapeutics, 32(4), 626–636. https://doi.org/10.1016/j.clinthera.2010.04.012
Chicago
Frame, James N., Lawrence Rice, John R. Bartholomew, and Andrew Whelton. 2010. “Rationale and Design of the PREVENT-HIT Study: A Randomized, Open-Label Pilot Study to Compare Desirudin and Argatroban in Patients with Suspected Heparin-Induced Thrombocytopenia with or without Thrombosis.” Clinical Therapeutics 32 (4): 626–36. doi:10.1016/j.clinthera.2010.04.012.